Petros Pharmaceuticals (PTPI) Competitors $0.02 0.00 (-7.29%) As of 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. LIPO, WINT, PRFX, VRAX, GLMD, GTBP, ELAB, ORGS, ATXI, and CDTShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Lipella Pharmaceuticals (LIPO), Windtree Therapeutics (WINT), PainReform (PRFX), Virax Biolabs Group (VRAX), Galmed Pharmaceuticals (GLMD), GT Biopharma (GTBP), PMGC (ELAB), Orgenesis (ORGS), Avenue Therapeutics (ATXI), and CDT Equity (CDT). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Its Competitors Lipella Pharmaceuticals Windtree Therapeutics PainReform Virax Biolabs Group Galmed Pharmaceuticals GT Biopharma PMGC Orgenesis Avenue Therapeutics CDT Equity Lipella Pharmaceuticals (NASDAQ:LIPO) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk. Which has stronger earnings and valuation, LIPO or PTPI? Lipella Pharmaceuticals has higher earnings, but lower revenue than Petros Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$536.36K5.19-$5.02M-$3.43-0.18Petros Pharmaceuticals$5.11M0.14-$8.16M-$52.910.00 Does the media refer more to LIPO or PTPI? In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score. Company Overall Sentiment Lipella Pharmaceuticals Neutral Petros Pharmaceuticals Neutral Is LIPO or PTPI more profitable? Petros Pharmaceuticals has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Petros Pharmaceuticals' return on equity of -78.22% beat Lipella Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-988.83% -224.08% -172.88% Petros Pharmaceuticals N/A -78.22%-23.50% Which has more risk and volatility, LIPO or PTPI? Lipella Pharmaceuticals has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Do insiders and institutionals hold more shares of LIPO or PTPI? 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 8.2% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryPetros Pharmaceuticals beats Lipella Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$714K$983.40M$6.12B$10.64BDividend YieldN/A4.84%5.66%4.69%P/E Ratio0.001.2886.1127.75Price / Sales0.1431.01588.17183.92Price / CashN/A17.6438.3262.20Price / Book0.017.3812.976.80Net Income-$8.16M-$7.96M$3.30B$275.97M7 Day PerformanceN/A34.47%3.27%2.08%1 Month PerformanceN/A30.85%10.12%9.09%1 Year PerformanceN/A-5.54%83.41%36.72% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros PharmaceuticalsN/A$0.02-7.3%N/A-99.7%$714K$5.11M0.0020Gap DownLIPOLipella Pharmaceuticals0.7692 of 5 stars$0.62-3.9%N/A-81.2%$2.84M$536.36K-0.154Gap DownWINTWindtree Therapeutics1.97 of 5 stars$0.10+2.8%$350.00+364,483.3%-99.6%$2.82MN/A0.0030Gap UpPRFXPainReform1.2642 of 5 stars$1.38-0.7%N/A-45.9%$2.78MN/A-0.014Analyst ForecastVRAXVirax Biolabs Group3.0365 of 5 stars$0.64+1.6%$3.00+369.5%-62.1%$2.77M$10K0.005Positive NewsGLMDGalmed Pharmaceuticals1.9416 of 5 stars$1.55-3.7%N/A-60.2%$2.56MN/A-0.0920News CoveragePositive NewsAnalyst ForecastGap UpGTBPGT Biopharma1.9562 of 5 stars$0.72+2.4%$11.00+1,421.4%-63.7%$2.53MN/A-0.178Analyst ForecastHigh Trading VolumeELABPMGC0.7995 of 5 stars$5.95+10.1%N/A-98.8%$2.50M$1.71M-0.0118News CoveragePositive NewsAnalyst ForecastGap UpHigh Trading VolumeORGSOrgenesisN/A$0.50+400.0%N/A-77.4%$2.40M$662K0.00150ATXIAvenue Therapeutics2.0772 of 5 stars$0.75+6.9%N/A-64.1%$2.38MN/A0.044CDTCDT Equity0.1865 of 5 stars$0.76-8.7%N/A-99.6%$2.32MN/A0.003News CoverageAnalyst ForecastStock SplitGap Down Related Companies and Tools Related Companies Lipella Pharmaceuticals Competitors Windtree Therapeutics Competitors PainReform Competitors Virax Biolabs Group Competitors Galmed Pharmaceuticals Competitors GT Biopharma Competitors PMGC Competitors Orgenesis Competitors Avenue Therapeutics Competitors CDT Equity Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
